Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1465-1472

  Doo, Nicole Wong ^a   Thompson, Philip A ^b   Miles Prince, H ^a,c   Seymour, John F ^a,c   Ritchie, David ^a,c   Stokes, Kerrie ^a   Burbury, Kate ^a   Wolf, Max ^a   Joyce, Trish ^a   Harrison, Simon J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autologous stem cell transplant; Bortezomib; Multiple myeloma; Salvage therapy

Indexed keywords

BORTEZOMIB; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; BORONIC ACIDS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84879335940     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.746682     Document Type: Article

References (26)

1. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99 :731-735. Morris (Pubitemid 34525530)
2. C, Drake M, Apperley J, et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica 2010;95:2126-2133.
3. Nemec P, Zemanova Z, Kuglik P, et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012;53:920-927.
4. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119 : 687-691.
5. Carreras E, Rosinol L, Terol MJ, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448-1454. (Pubitemid 350091380)
6. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 57-65.
7. H onma K, T suzuki S, N akagawa M, et al. T NFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
8. Jimenez-Zepeda V, Mickhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012;18:773-779.
9. Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012;118:3549-3555.
10. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084-1089.
11. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and eff ective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-422.
12. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft Bone Marrow Transplant 1998;21:887-892.
13. Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011;52:1455-1462.
14. L onial S, K aufman J, T ighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose-and schedule-finding study. Clin Cancer Res 2010;16:5079-5086.
15. Roussel M, Moreau P, Huynh A, et al. Bortezomib and highdose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-37.
16. Lee SR, Kim SJ, Park Y, et al. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010;45:183-187.
17. Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012;157:553-563.
18. Th ompson PA, Prince HM, Seymour JF, et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011;46:764-765.
19. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144. (Pubitemid 36323723)
20. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-2380. (Pubitemid 36302084)
21. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 ; 20:1467-1473. (Pubitemid 44264086)
22. R ichardson P G, S onneveld P, S chuster M W, et al. B ortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
23. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
24. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502. (Pubitemid 38010075)
25. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441. (Pubitemid 46999214)
26. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30 : 2946-2955.